[New] Pharmaceutical sponsors are becoming more selective in vendor qualification, prioritizing manufacturers with strong compliance track records and global regulatory approvals to minimize the risk of supply disruption.
Persistence Market Research
[New] Fastest-Growing Service Type: Integrated CDMO services are expected to register a CAGR of around 9.1% from 2026 to 2033, owing to pharmaceutical companies consolidating vendors to accelerate development-to-commercialization timelines.
Persistence Market Research
[New] Leading Service Type: Drug substance manufacturing is expected to account for roughly 44% of revenue share in 2026, driven by increasing outsourcing of biologics and complex-molecule production, which require specialized infrastructure.
Persistence Market Research
[New] The Indian Pharmaceutical industry is projected to reach USD 130 billion by 2030 from USD 60 billion in 2026, showing rising future demand of precision fermentation technology.
Polaris
[New] The use of artificial intelligence in drug R&D will allow for quicker identification of targets, selection of candidates, and design of clinical trials.
tradingkey.com
[New] A share of nearly 63.2% is expected to be held by the U.S. in 2026, attributed to increasing research in DNA nanorobots, smart drug delivery systems, and AI-integrated nanomedical devices.
Persistence Market Research
[New] Some 12% of Americans are taking a GLP-1 drug, helping convince millions of users and the many people who have watched their transformation that the key to health, beauty and longevity might come in a syringe.
Bloomberg
[New] Injectable GLP-1 drugs turned Novo Nordisk and Eli Lilly into two of the most important pharmaceutical companies in the world, but injections were always going to limit adoption for some patients.
Windows Forum
[New] In 2026, total prescription drug spending growth is expected to slow to a rate of 5.1% due to Inflation Reduction Act provisions.
Fortunly
Drug-resistant infections could contribute to 39 million deaths in the coming decades if effective interventions are not implemented.
Innovation News Network
Axios reports next month's weight-loss drug coverage program may unleash pent-up demand for Wegovy, Zepbound and other treatments, even as clinicians warn they do not have the staffing to absorb a prescribing rush.
MM+M - Medical Marketing and Media
European marketing authorisation is expected within weeks, and a US pivotal trial has been initiated with first data due in 2027 and a New Drug Application planned for 2028.
Business of Cannabis
Without broader investment in manufacturing capacity and R&D, Chile's pharmaceutical export base will remain narrow and structurally constrained.
Fitch Solutions
Although there have been evolving treatment options, including a recently accelerated approval by the U.S. Food and Drug Administration, or FDA, of dordaviprone, the typical estimated survival post-diagnosis is a mere 9 to 15 months, and only 30% of patients are expected to live a full year.
SenCanada
MIT researchers have demonstrated a low-cost design of specialized electronic nozzles, called triaxial electrospray emitters, that could be used to manufacture time-release drug-delivery particles or self-healing materials efficiently and at scale.
MIT News | Massachusetts Institute of Technology
The FDA recently released a warning letter alerting life science orgs to the risks of using and advising against overreliance on AI in drug manufacturing.
Forrester
Opdivo, with $7.1 billion in sales, is expected to lose patent protection in 2028 alongside Keytruda, creating a second major PD-1 checkpoint inhibitor biosimilar opportunity.
Life Science Daily News
Last updated: 07 July 2026
Hi,
Would you like a quick online demo of our service from an experienced member of our team?
